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Activation of ~ 3 4 " ~ " ~  Protein Kinase by Microinjection of Human 
cdc25C into Mammalian Cells 
REQUIREMENT FOR PRIOR PHOSPHORYLATION OF cdc25C BY p34'd'2 ON SITES PHOSPHORYLATED 
AT MITOSIS* 
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Human cdc26C  protein,  a specific tyrosine phospha- 
tase  that activates the ~ 3 4 " ~ " '  protein kinase at  mitosis, 
is itself a  phosphoprotein  that shows increased  phos- 
phorylation  during  the Gz-M transition. In vitro, 
cdc25C  protein is substantially  phosphorylated  by  pu- 
rified p34d'2-~y~lin B protein kinase. Of seven puta- 
tive phosphorylation sites for ~ 3 4 ~ " ~  protein kinase 
present  in  human  cdcZSC, five are phosphorylated by 
~ 3 4 ~ " ~  protein kinase in  vitro, as assessed  by  tryptic 
phosphopeptide  mapping  and  peptide  sequencing. 
These  same sites are also phosphorylated in  vivo dur- 
ing  the G2-M transition  in  normal  mammalian  fibro- 
blasts and have been precisely mapped. The cdc25C 
phosphorylated in  vitro by ~ 3 4 ~ " '  protein kinase ex- 
hibits a 2-%fold higher activity than the nonphos- 
phorylated cdcZSC, as assayed  by activation of inactive 
cdc2  prokinase.  Microinjection  of  purified  cdc25C  pro- 
teins into living fibroblasts reveals that  only  the  phos- 
phorylated  form  of cdc26 is highly effective in activat- 
ing GZ cells into  premature  prophase  in  a  manner  sim- 
ilar to  microinjection  of  purified active ~ 3 4 " ~ " ~  protein 
kinase. Together  these  data  show  that  multisite  phos- 
phorylation of cdc25C  by p34cdcz-~y~lin B protein k i -  
nase occurs at the Gz-M transition  and is sufficient to 
induce  the  autoamplification  of  cdcZlM-phase  promot- 
ing  factor  necessary  to drive somatic  mammalian cells 
into  mitosis. 
The "phase promoting factor (MPF)' is a proline-directed 
serine/threonine protein kinase activated during the G2-M 
phase transition (reviewed in Nurse (1992), Doree (1990), 
Pines  and  Hunter (1990), and Lewin (1990)). Purification of 
MPF by  following histone H1 kinase activity had led to  the 
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identification of two different subunits, ~ 3 4 " ~ " '  and cyclin B 
(Labbe et d., 1989a, 1989b; Lohka et d., 1988). Whereas the 
~ 3 4 ~ ~ ~ '  subunit is responsible for the catalytic activity, cyclin 
B is necessary to form and  maintain the active enzyme and 
perhaps designate cellular localization and/or  substrate spec- 
ificity. Prior to formation of the active kinase, the ~ 3 4 " ~ ' -  
cyclin B protein complex exists in an inactive form called 
"pre-MPF"  (or "prokinase"), in which  cdc2 is phosphorylated 
within the strongly conserved NH2-terminal region  on tyro- 
sine  and additionally on threonine in vertebrate cells 
(GEGT(P)Y(P)GVV) (Draetta et d., 1988; Krek and Nigg, 
1991; Morla et ~ l . ,  1989; Norbury et d.,  1991). The phos- 
phorylation and subsequent dephosphorylation of these resi- 
dues seem to be important in coupling DNA replication and 
mitosis (Enoch  and Nurse, 1990; Dasso and Newport, 1990). 
Mutation of the ~ 3 4 " ~ " '  tyrosine 15 residue to phenylalanine 
(cdc2 F15) causes p34'd'2 premature incomplete prophase 
events  during the cell  cycle of the fission yeast Schizosacchar- 
omyces pombe (Gould and Nurse, 1989) and in HeLa cells 
(Krek and Nigg, 1991). The universality of this mechanism is 
unclear, since in Saccharomyces cereuisiae, mutations that 
prevent tyrosine phosphorylation do not lead to premature 
mitosis and do not abolish feedback controls (Sorger and 
Murray, 1992; Amon et d., 1992). Recently, the enzymatic 
activities that modulate the reversible phosphorylation of 
p34ch2-tyrosine 15 have been described. Phosphorylation is 
promoted by a kinase pathway involving wee1 and mikl 
(Lundgren et d., 1991), whereas dephosphorylation involves 
a  phosphatase that requires the cdc25  gene product (reviewed 
in Millar and Russel (1992)). Various reports have demon- 
strated  that tyrosine dephosphorylation and kinase activation 
could be triggered in vitro  by bacterially expressed and highly 
purified human cdc25 (Strausfeld  et ~ l . ,  1991; Gautier et ~ l . ,  
1991; Dunphy  and Kumagai, 1991; Millar et ~ l . ,  1991b;  Lee et 
d ,  1992). Moreover, a motif (HCXXXXXR) was described, 
which is conserved between the cdc25 family and known 
tyrosine phosphatases (Moreno and Nurse, 1991; Strausfeld 
et d.,  1991). Mutations of the cysteine or arginine residues in 
the HCXXXXXR motif, which is localized in the active 
catalytic domain near the COOH terminus, abolish the in vivo 
activity of cdc25 and its phosphatase activity in vitro (Gautier 
et d., 1991; Millar et ~ l . ,  1991b;  Lee et al., 1992). Despite the 
fact that, in uiuo, cdc25 seems to act specifically  on ~34"~"-  
cyclin B, other  substrates used to measure phosphatase activ- 
ity, such as  p-nitrophenyl  phosphate (Dunphy and Kumagai, 
1991) or casein-phosphorylated or serine residues (Millar et 
~ l . ,  1991b), can also be dephosphorylated. 
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Since cdc25 appears to be involved in the activation of 
p34cdcz kinase, various studies have examined the modalities 
of how this is brought about. Although some reports have 
described that  the level of cdc25 mRNA increases during Gz 
in fission yeast (Ducommun et al., 1990; Moreno et al., 1990) 
and HeLa cells (Sadhu et al., 1990), the abundance of cdc25 
protein is not cell cycle-regulated in Xenopus embryos (Jessus 
and Beach, 1992), HeLa cells (Millar et al., 1991a), or in 
nontransformed rat embryo (REF-52)  or  human fibroblasts 
(HS-68) (Girard et al., 1992). Therefore cdc25, like ~34"~"', 
seems to be present at a  constant level throughout the cell 
cycle, and the question arises how cdc25 activity is regulated 
with respect to  the timing of MPF activation. The physical 
association between cdc25 and  the p34cd"2-cyclin B complex 
oscillates during the cell cycle, reaching a peak at M-phase 
(Gautier et al., 1991; Jessus  and Beach, 1992). However, since 
in fission yeast p80cdc25 is a phosphoprotein that is predom- 
inantly phosphorylated on serine (Moreno et al., 1990) and 
cdc25 protein appears to be heavily phosphorylated during 
"phase in Xenopus oocytes (Gautier et al., 1991), various 
reports have investigated whether phosphorylation might reg- 
ulate cdc25 phosphatase activity both in uitro and in uiuo. In 
Xenopus, phosphorylation of cdc25 proteins by an unidenti- 
fied kinase activity present  in mitotic extracts is sufficient to 
bring about the activation of cdc25 phosphatase activity 
against both artificial substrates  and ~ 3 4 ' ~ ' ~  kinase (Kumagai 
and Dunphy, 1992; Izumi et al., 1992). More recently, Hoff- 
mann et al. (1993) reported that bacterially expressed human 
cdc25C proteins could be phosphorylated by a kinase activity 
present in HeLa cell mitotic extracts, an event that also seems 
to bring about an increase in cdc25 phosphatase activity as 
measured in vitro against artificial substrates and in uiuo by 
its ability to induce Xenopus oocyte maturation. Based only 
on indirect evidence the  authors suggested that  ~34'~'' kinase 
would  be the kinase responsible for this mitotic phosphoryl- 
ation of human cdc25C in HeLa cells.  However,  no evidence 
was provided for the number or location of the sites of 
phosphorylation on cdc25C or that such phosphorylation of 
cdc25C had any effect on its activity in uiuo in mammalian 
cells. In the present report, we show that human cdc25C 
protein is phosphorylated in uiuo in  human fibroblasts during 
mitosis at  the same six sites  as  are phosphorylated, in uitro, 
by  highly purified p34'dcz-cyclin B kinase. Phosphorylation of 
cdc25C increases 2-3-fold its activation of cdc2-cyclin B  pro- 
kinase in vitro. Furthermore, we demonstrate that after phos- 
phorylation by p34cd"2-cyclin B, cdc25C protein is capable of 
activating the endogenous ~34"~" '  prokinase when microin- 
jected into Gz cells, an effect not observed with the nonphos- 
phorylated protein, showing that only the phosphorylated 
form of cdc25C is effective in uiuo. 
EXPERIMENTAL  PROCEDURES 
Enzyme Purification-Active M-phase-specific H1 histone kinase 
(MPF) was prepared from starfish oocytes at first meiotic metaphase 
as described (Labbe et al., 1991). Prokinase (pre-MPF), phosphoryl- 
ated on p34dz-tyrosine 15/threonine 14 and inactive as  H1 histone 
kinase, was purified as a  p34'~2-cyclin  B complex from Gn-arrested 
starfish oocytes (Strausfeld et al., 1991). Human cdc25C  gene product 
(Sadhu et al., 1990) was overexpressed in bacteria as previously 
described (Strausfeld  et al., 1991). cdc25C protein was either purified 
from the inclusion bodies by denaturation/renaturation or from the 
soluble fraction of bacteria induced at low temperature. Proteins 
purified from the inclusion bodies were denatured  in  9 M guanidine 
hydrochloride in buffer containing 40 mM HEPES, 5 mM EDTA, 5 
dialysis acainst 500 mM NaC1. 40 mM HEPES, 5 mM EDTA, 5 mM 
mM DTT at pH 7.5. Protein renaturation consisted of extensive 
DTT at ~ I H  7.5. 
Phosphorylation of cdc25C Protein  in Competition  with Histone HI 
and Trypsin Inhibitor by Purified p34&'-Cyclin B K i m e   I n  Vitro- 
Trypsin  inhibitor (Boehringer Mannheim) and histone H1 (Boehrin- 
ger Mannheim) were mixed together with purified human cdc25C 
protein  in buffer containing 50 mM HEPES, 200 mM NaCl, 10 mM 
MgCL, 0.2 mM [Y-~'P]ATP (100 cpm/pmol), 1 mM DTT in a final 
volume of 25 gl. Different concentrations of substrates were used, as 
described in the legend for Fig. 1. Phosphorylation reaction was 
started by adding 0.05  pg  of active p34&'-cyclin B kinase. After 30, 
60,  120, and 240 s of incubation at 25  "C, 3-pl aliquots of the phos- 
phorylation reaction were stopped in Laemmli sample buffer. Phos- 
phorylated proteins were separated on 10% SDS-PAGE and  stained 
with Coomassie Brilliant Blue, and dried gels  were autoradiographed 
at -70  'C. 
Cell Culture and Labeling-Rat embryo fibroblasts (REF-52 cells) 
were cultured in Dulbecco's modified Eagle's medium and supple- 
mented with 10% fetal calf serum as described previously (Lamb  et 
al., 1990). Cells were subcultured onto acid-washed glass coverslips 
and allowed to grow for 2 days prior to use. Cells were synchronized 
into  GI or G, by serum deprivation and hydroxyurea blocking prior 
to S-phase as described previously (Girard et al., 1991). For in vivo 
labeling, cells were subcultured onto 25-mm-diameter coverglasses 
(-2 X lo6 cells), and after synchronization into G, coverglasses were 
transferred to humidified chambers overlaid with 100 pl of phosphate- 
free culture media containing 300-500 pCi of 3ZP-labeled 0,. Cells 
were harvested as  the mitotic index attained 10% or greater. Similar 
results were obtained using cells mechanically detached from flasks 
in mitotic shakes. Labeled cells were analyzed by two-dimensional 
electrophoresis using an Ampholine pH gradient of  4-7 and subjected 
to Western immunoblotting as described previously (Girard et al., 
1991). Antisera used to identify cdc25C were the same as those 
described previously (Girard et al., 1992) except that the antisera 
were affinity purified against cdc25C protein. The specificity of the 
signal for cdc25C  was confirmed by blocking the antisera prior to use 
with purified cdc25C proteins that completely abolished the blotting 
signal. 
Determination of p34&'-Cyclin B Phosphorylation Sites on 
cdc25C"Human cdc25C protein (10-50 pg/assay) were mixed with 
0.5 pg  of p34&'-cyclin B kinase in 50 mM glycerophosphate, 10 mM 
MgC12,7 mM EGTA, 0.5 mM [32P]ATP mix (100 cpm/pmol) in 50  pl. 
After phosphorylation of human cdc25C protein by  p34'*2-cyclin B 
kinase for 1 h, the reaction was stopped by addition of either 0.2  mg/ 
ml TPCK-treated trypsin (Worthington) in 200 mM ammonium 
bicarbonate final concentrations  or 100 mM Tris-HC1, pH 7.4, 0.1% 
SDS, and 0.15 mg/ml chymotrypsin (Worthington) and further in- 
cubation for 24 h at 30  "C. Incompletely digested peptides eluting late 
during HPLC were  pooled, lyophilized, and further digested with 0.15 
mg/ml trypsin. Alternatively, to ensure the absolute comparability of 
the in vivo and in vitro peptides, in vitro phosphorylation of cdc25C 
was stopped by addition of boiling sample buffer, and  the proteins 
were analyzed by one- and two-dimensional electrophoresis before 
complete tryptic digestion as described for phosphopeptide mapping 
(see below). The peptide mixture was injected into  an Aquapore C8 
reverse-phase microbore column (0.21 x 10 cm) equilibrated with 
0.1% trifluoroacetic acid using a Brownlee microgradient system. 
Elution was carried out  at 0.2 ml/min with a 60-min gradient between 
solvent A (0.1% trifluoroacetic acid) and solvent B (0.08% trifluoro- 
acetic acid, 60% acetonitrile).  Elution was  followed  by monitoring the 
absorbance at 220  nm with a Spectraflow 773 detector (Kratos Brown- 
lee). Radioactivity of individual fractions was determined by Ceren- 
kov counting. Tubes containing radioactive peptides were further 
purified by HPLC on a C18 column (0.21 X 10 cm) using shallow 
gradients. Purified peptides were concentrated by vacuum centrifu- 
gation and loaded onto Polybrene-coated glass fiber discs. Microse- 
quencing was carried out on an Applied Biosystems 470A gas phase 
sequenator coupled on-line to a 120A phenylthiohydantoin analyzer. 
Phosphoserine was detected by the presence of the dithiothreitol 
adduct of dehydroalanine (D-Ser) and the absence of authentic 
phenylthiohydantoin-Ser (Meyer et al., 1991) (sites 3, 5, and 6). 
Phosphothreonine was indirectly determined either as unique Thr 
residues present in the  parent peptides (sites 2 and 4) or after positive 
identification of other unlabeled Thr residues (site  1, Thr  at steps 2 
and 5). 
Two-dimensional Phosphotryptic Mapping-Zn vitro or in vivo la- 
beled cdc25C protein was excised from dried gels or Immobilon 
membranes and digested with 0.2 mg/ml trypsin (TPCK-treated) in 
200 mM ammonium bicarbonate. Digestion at 37 "C overnight was 
continued by the addition of fresh trypsin for 12 more h. The 
supernatant from this complete tryptic digestion was counted (80% 
of initial counts were recovered) and lyophilized three times with 
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resuspension in distilled water. Phosphopeptides were either used for 
two-dimensional peptide mapping or purified by HPLC for gas phase 
sequencing. Individual purified phosphopeptides isolated by HPLC 
for sequencing were also subjected to one- and two-dimensional 
peptide mapping. Phosphopeptides were separated by electrophoresis 
at  pH 1.9 for 40 min at 950 V in the first dimension followed by 
ascending chromatography with isobutyric acid buffer (isobutyric 
acidbutanol:pyridine:acetic acidwater, 65:2:5:3:29) (described by 
Boyle et al. (1991)). 
Phosphoamino Acid Analysis-After autoradiography, phospho- 
peptides were individually recovered from TLC plates in 50% pyri- 
dine. Following lyophilization of the  supernatant 32P-labeled peptides 
were hydrolyzed with 5.7 M HCI for 2 h at 110 "C and dried, and 
phosphoamino acids were separated by one-dimensional electropho- 
resis a t  pH 3.5 (Boyle et al., 1991). 
Phosphorylation of cdc25 Protein by p34&'-Cyclin B Kinase and 
Immunoprecipitation of p34&'-Cyclin B Kinase-For use in microin- 
jection studies, 12 pg  of human cdc25C protein were incubated with 
~34~ ' -cyc l in  B kinase (final specific activity, 50 pmol/pl/min phos- 
phate molecules incorporated into histone H1, -0.015 mg/ml) (reac- 
tion 1 + 2)  or alone (reaction 3), together with 1 mM ATP (reaction 
1 + 3)  or ADP (reaction 2) in 50 p1 of HMD buffer (10 mM HEPES, 
pH 7.5,lO mM MgClz, 5 mM D m ) .  After 1 h of incubation at  25  "C, 
affinity-purified anti-starfish cyclin B antibody, coupled to 10 pl of 
protein A-Sepharose beads (Strausfeld et al., 1991) in HMD buffer, 
was added (final volume, 100 pl), and each assay was further incubated 
for 30 min at 25 "C. After separation of beads and  supernatant, beads 
were washed 3 times and kept in HMD buffer at 0 "C as was the 
supernatant. 
Western blotting-Proteins were separated on 11% SDS-PAGE, 
transferred to nitrocellulose, and probed with affinity-purified anti- 
bodies as described previously (Girard et al., 1991,1992). After binding 
of primary antibodies (anti-EGVPSTAIREISLLKE peptide = "anti- 
PSTAIR described in  Strausfeld et al. (1991)), peroxidase-conjugated 
anti-rabbit antibody (Amersham Corp.) was added (1/10,000) for 1 h. 
Affinity-purified and biotinylated anti-human cdc25C antibody was 
incubated with peroxidase-conjugated ExtrAvidin (Sigma) 1:6000 for 
1 h. Detection of the immune signal was performed with the ECL 
Western blotting detection system (Amersham Corp.). 
In Vitro Phosphatase Assay  Using Prokinase Activatwn-The in 
vitro activation of starfish cdc2 prokinase (the cyclin B-cdc2 protein 
kinase complex containing phosphate on both threonine 14 and 
tyrosine 15) was performed as described earlier (Strausfeld et al., 
1991). Essentially, purified cdc2-phosphorylated and unphosphory- 
lated cdc25C proteins prepared as described above were dialyzed into 
a buffer consisting of  40 mM NaHC03, 0.3 M NaC1,2 mM DTT  at pH 
7.4 without ATP, and the concentration of cdc25C proteins was 
equilibrated. Prokinase activation assays were performed by incubat- 
ing for the indicated times at 20 "C 1 volume of inactive starflsh 
prokinase (5 pg/ml) with 1 volume of the cdc25C protein solution (50 
pg/ml) in 6 pl of reaction mixture. After the appropriate incubation 
period an aliquot (2 pl)  of this reaction mixture was removed and 
assayed for histone 1 kinase activity by the addition of  40 pl of 1.0 
mg/ml histone H1 in a buffer containing 0.2 mM ATP/[32P]ATP (50 
cpm/pmol), 10 mM MgC12 in 20 mM HEPES  pH 7.4. Incorporation 
into histone H1 was measured as described before (Labbe et al., 
1989a). 
Microinjection of cdc25C Protein and Zmmunofluorescence-Cells 
were microinjected with 0.5-pm outer  diameter micropipettes pulled 
on a linear horizontal puller and microinjected on Leitz inverted 
microscope equipment with a manual Leitz micromanipulator. 30-50 
cells were injected per experiment. When indicated, cells were treated 
with 0.1 pM okadaic acid in Dulbecco's modified Eagle's medium 
applied as they were injected. Cells were stained  for cdc25 as described 
previously (Girard  et al., 1992). The polyclonal anti-cdc25 antibody 
was monospecific for cdc25C as determined by immunoblot analysis. 
Cells were mounted and photographed as described previously (Lamb 
et al., 1990). 
RESULTS 
Purified human cdc25 is specifically phosphorylated by 
p34c&2-cyclin B kinase in uitro. Analysis of the derived amino 
acid sequence of the cdc25C protein (Sadhu et al., 1990) 
reveals several potential consensus sites for phosphorylation 
by p34dc2-cyclin B kinase ("S/T-P" sites; shown for human 
cdc25C in Fig. 4). To  test if these are phosphorylated, we have 
performed in uitro phosphorylation assays in which bacterially 
produced and highly purified and active human cdc25C phos- 
phatase was incubated with p34'dc2-cyclin €3 kinase. Highly 
purified cyclin B-associated cdc2 kinase was isolated from 
starfish oocytes as described earlier and shows only two 
homogeneous bands  on  a gel, one at 34 kDa corresponding to 
cdc2 kinase catalytic  subunit  and one at 45 kDa corresponding 
to cyclin B (Labbe et al., 1989a, 1991). Fig. L4 shows an 
autoradiograph of a gel analyzing phosphorylation reaction 
mixtures in which 0.1 mg/ml  cdc25 has been incubated with 
~34~ ' -cyc l in  B kinase (60 pmol/pl/min final) in the presence 
of varying amounts of the alternative  substrate histone H1 
and 1 mg/ml trypsin inhibitor. The first set of jour lanes 
contains the molecular weight markers  and each of the  three 
substrate components alone stained by Coomassie Blue to 
show their respective molecular mass with their degradation 
products  (in the case of cdc25 and Hl).  The next three sets of 
four lunes on Fig. 1 then  represent the kinetics (30, 60,  120, 
and 240 s) of phosphorylation by ~ 3 4 ' ~ ' ~  protein kinase of the 
different substrates with the concentration of H1 in the 
reaction mixture being, respectively, 0.01, 0.1, and 1 mg/ml. 
Phosphorylation reactions were stopped by the addition of 
boiling SDS sample buffer. These reaction mixtures show a 
linear increase in phosphorylation of cdc25 protein by ~ 3 4 ' ~ ' ~  
protein kinase beginning to plateau by  240 s in all three cases. 
Incorporation of radioactive phosphate  into histone H1 and 
cdc25 protein reaches similar levels when equal concentra- 
tions of these two substrates were used. The quantitative 
representation of the kinetics of phosphorylation of cdc25 is 
shown in Fig.  1B. Labeling of cdc25C still reached the same 
level even in the presence of a 10-fold excess of H1 (Fig. lA, 
lanes 1-1 0 and Fig. lB, curue 1 / l o ) .  Assuming a plateau value 
of -2500  cpm for 3 pl of reaction mixture (i.e. 0.3 pg  of cdc25 
protein), we calculated that 4-5  mol  of phosphate were incor- 
porated per mol of cdc25C protein. The phosphorylation of 
cdc25 protein  and  histone H1 was specific, since no incorpo- 
ration of phosphate  into  trypsin  inhibitor was observed, even 
though it was always present in the reaction mixtures (at 1 
mg/ml) and contains one potential consensus site (SP) for 
phosphorylation by ~ 3 4 ' ~ ~ - c y c l i n  B kinase. It is to be noted 
that  in all  incubations  a slight level of autophosphorylation 
by  cdc2 kinase on its cyclin B  subunit (at 45 kDa, marked by 
an asterisk) is detectable. In control assays in which cdc25 
was omitted, no phosphorylation of the cdc25 protein band at 
60 kDa and of a minor breakdown product band visible at 40 
kDa occurred (data  not shown). Together, these data show 
that cdc25 protein is phsophorylated by p34cdc2-cyclin B ki- 
nase in  a highly efficient manner in uitro even in the presence 
of a 10-fold excess of competing histone H1 substrate. 
cdc25 Protein Is Phosphorylated on the Same  Sites at Mi- 
tosis and by p34"dc2-Cyclin B Kinase-We next examined the 
patterns of phosphorylation of cdc25 protein in growing mam- 
malian cells. Several recent reports have described an in- 
creased phosphorylation of cdc25 proteins  during the G2-M 
period in Xenopus oocytes (Kumagai and  Dunphy, 1992; Izumi 
et al., 1992) and in transformed mammalian (HeLa) cells 
(Hoffmann et al., 1993). We have performed an analysis of 
the  patterns of phosphorylation in human nontransformed 
fibroblasts (HS-268) at G2 and G2-M after separation on 
denaturing high resolution two-dimensional gels. This  analy- 
sis was essential since the molecular mass of cdc25 proteins 
(55-70 kDa) is coincidental with a number of cytoskeletal and 
structural  phosphoproteins such as nuclear lamins, vimentin, 
and  cytokeratins that increase their phosphorylation state at 
mitosis. Identification of the localization of cdc25 proteins 
was made by immunoblotting proteins  after electrophoretic 
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FIG. 1. Human cdc26 protein is phosphorylated in vitro by 
p34"dc2-cyclin B kinase. Highly purified p34'd'2-cyclin B kinase 
was incubated with purified bacterially expressed human cdc25 pro- 
tein, histone H1, and 1 mg/ml trypsin inhibitor in  the presence of 
[32P]ATP  as described under  "Experimental Procedures." The protein 
concentration of histone H1 relative to cdc25 was varied from 0.1- to 
10-fold, as indicated, where 1 is equivalent to a final protein concen- 
tration of 0.1 mg/ml. Aliquots of the reaction were stopped after 30 
( I ) ,  60 (2) ,  120 (3), and 240 ( 4 )  s. Proteins were separated on 11% 
SDS-PAGE, and  the gel was stained, dried, and autoradiographed. A,  
in the first 4 lanes each substrate component of the phosphorylation 
reaction was run alone and is shown as Coomassie Blue stained  on 
the left next to  the marker protein. Lane 2, cdc25; lane 3, trypsin 
inhibitor (Tryp In); lane 4, histone H1. Next three sets of 4 lanes, 
autoradiograph of the gel showing the phosphorylation reactions. The 
position of starfish cyclin B subunit (45  kDa),  detectable  through its 
autophosphorylation, is shown with an asterisk. B,  protein bands 
shown in panel A corresponding to cdc25 were excised, and their 
radioactivity was quantified by Cerenkoff counting. 
separation using one of three different antisera raised  against 
either  human cdc25C protein expressed in bacteria or syn- 
thetic  peptides corresponding to  the  catalytic  sites of cdc25 
proteins  (Girard et al., 1992). Fig. 2 shows a typical  electro- 
phoretic  pattern  obtained  after  blotting with  anti-cdc25 
(panels B and D) and  the associated protein phosphorylation 
pattern for the  same region of the blots  from cells in either 
Gz (3 h after release from hydroxyurea  block) (Girard et al., 
1991) or G,-M (7  h after release from hydroxyurea block) 
(panels A and C). The position of vimentin, one of the major 
phosphoproteins  in fibroblasts, is shown by an arrow. This 
position was precisely determined by reprobing the same 
membrane with  monoclonal anti-vimention  antibodies (Boeh- 
ringer Mannheim) and clearly illustrates the difficulty in 
studying  the in  vivo phosphorylation of cdc25 in human cells 
by only  one-dimensional separation of the proteins. On two- 
dimensional separation, cdc25 in G, cells resolved as a major 
spot  migrating at   the same molecular mass  as vimention and 
just slightly basic of the  most basic isoform of vimentin (panel 
B ) .  Clearly, cdc25 proteins undergo a marked increase in 
phosphorylation as cells enter mitosis  in  a manner similar to 
that described for other cell systems,  and  this  correlates with 
the  appearance of a  second  more acidic spot  as detected by 
immunoblot (compare panels A and B and C and D) in Fig. 
2). I t  can be noted that, in the presence of urea in the sample 
buffer used for two-dimensional  electrofocusing, the  apparent 
decrease in electrophoretic mobility observed for the phos- 
phorylated cdc25C proteins in one-dimensional gels is not 
seen. A similar  result can be observed in  one-dimensional gels 
through simple  inclusion of urea  in the sample or gel buffer 
(data  not  shown). 
To determine if the pronounced  increase in phosphoryla- 
tion seen  in Gz-M cells occurred at   the same  sites  as  those 
phosphorylated in vitro by ~ 3 4 ' ~ ' ~  protein kinase, cdc25 phos- 
phoproteins from HS-68 mitotic cells or cdc25C proteins 
phosphorylated in vitro by p34'd''-cyclin B were excised from 
two-dimensional gels and subjected to complete tryptic diges- 
tion. Phosphopeptides were then analyzed by two-dimen- 
sional peptide  mapping  and  HPLC  separation techniques and 
sequenced. Phosphopeptide maps shown in Fig. 3 revealed 
that  the  patterns of distribution of phosphopeptides are very 
similar, with four to five predominant phosphopeptides in 
both cases  (Fig. 3, A and B ) .  When  the two sets of peptides 
(from in vitro and in uiuo phosphorylation) were mixed and 
run  together with the  same technique, five phosphopeptides 
(numbered 1, 2, 3-4, 5, and 6) were found  comigrating (Fig. 
3, panel C) indicating  that  the  sites phosphorylated i n  vitro 
and in  uiuo are on the same tryptic peptides. To precisely 
identify the  threonine  or  serine residues within the  human 
cdc25C molecule phosphorylated by p34'd'2-cyclin B kinase, 
"P-labeled cdc25 protein was digested with trypsin,  and  the 
resulting phosphopeptides were purified by HPLC. Eluted 
peptides were individually  subjected to two-dimensional  map- 
ping  and  to gas phase sequencing. Fig. 4 presents  the complete 
amino acid sequence of human cdc25C with the relative 
position of seven  predicted  phosphorylation sites for ~34'~'' 
indicated  in boldface and numbered from 1 to 7 according to 
their position, starting at   the NH, terminus. Along this  se- 
quence, the sequence of five phosphopeptides as identified by 
microsequencing is indicated. In addition the phosphorylation 
of peptides 1, 3-4, 2, and 6 was also confirmed for highly 
purified cdc25C isolated from mitotic cells through mitotic 
shake. To further confirm the  identity of the different  phos- 
phopeptides,  phosphoamino  acid analysis was performed on 
individual peptides resolubilized from the TLC plates and 
showed that each phosphopeptide contained  the phosphoa- 
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FIG. 2. Two-dimensional  analysis of the electrophoretic mobility and phosphorylation of cdc25C proteins in human  fibro- 
blasts in G2 and  at G2-M transition. Human fibroblasts (HS-68) were grown, synchronized, and :”P-labeled as described under 
“Experimental Procedures.” After 90 min of labeling, cells were harvested in lysis buffer, and total cell extracts were analyzed by two- 
dimensional gel electrophoresis as described under  “Experimental Procedures.” Separated  proteins were then  transferred to nitrocellulose for 
immunoblotting with anti-cdc25  antibodies as described  previously (Girard et al., 1992). Shown  are  autoradiograms of the  blots from cells in 
GP (panel A )  and  in  late GP and M (panel C) with  their  corresponding  immunostaining for  cdc25 proteins as revealed by ECL (panels B and 
D, respectively). The positions of two  major  cytoskeletal  proteins,  vimentin (Vim) and  actin,  are shown by arrows. 
I B in vivo 
FIG. 3. Two-dimensional tryptic pept ide   maps   f rom  cdc25C  pro te in .  Purified cdc25C was phosphorylated in uitro with ~ 3 4 ~ ’ -  
cyclin B kinase  as described under  “Experimental Procedures.” Alternatively,  phosphorylated cdc25 was derived from 3ZP-labeled mitotic 
human  fibroblasts as described in Fig. 2. After labeling and  two-dimensional electrophoresis, phosphorylated cdc25 was excised from  the 
dried gels and subjected to  tryptic digestion followed by two-dimensional  separation of the  phosphopeptides  as described under  “Experimental 
Procedures.” Shown  are  autoradiograms of the  TLC  plates. Five major  phosphopeptides have  been  labeled 1,2,3-4,5, and 6 in correspondence 
with  their location in  the sequence of cdc25C as identified by microsequencing and  as indicated in Fig. 4. Panel A, tryptic  phosphopeptides 
from purified cdc25C labeled in uitro with ~ 3 4 ‘ ~ ’  kinase; panel B, tryptic cdc25 phosphopeptides from human  fibroblasts labeled in Gz-M; 
panel C,  mixture (mix) of the  samples described in panels A and B. Approximately 250 cpm were  loaded on  each plate. o marks  the origin. 
The direction of migration  in  the  first  dimension (e, for  electrophoresis, cathode  on  the  right)  and  in  the second  dimension (c, for ascending 
chromatography)  are  indicated  on panel A .  
mino acid predicted from the sequencing data with only consensus  sites  for  phosphorylation by p34‘d‘2-cyclin B kinase 
peptide 3-4 (see  position  on Figs. 3 and  4)  containing  both (Thr4’, Thr67, Ser”‘, Thr13’, Ser’=, and SerZl4) were indeed 
phosphoserine  and  phosphothreonine  (data  not  shown).  From found labeled in uitro. It can be noted from the sequencing 
these  data  it  is clear that six of the seven potential S/T-P data  that two of the  potential cleavage sites by trypsin, Arg4’ 
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FIG. 4. Analysis of p34*'-cyclin B kinase phosphorylation 
sites within the human cdc2SC protein. Radiolabeled tryptic 
peptides derived from human cdc25C phosphorylated in uitro by 
~34'~'' kinase were purified by HPLC and identified by microsequenc- 
ing (see "Experimental Procedures"). They are shown together with 
the complete human cdc25C amino acid sequence (amino acids 1- 
473; Sadhu et al. (1990)). Amino acid positions of seven putative 
phosphorylation sites for the p34&'-cyclin B kinase (SP or TP) are 
indicated in boldface and numbered above the human cdc25C se- 
quence. Of these seven potential sites, six have been found phos- 
phorylated in uitro and are indicated in boldface letters in the sequence 
of the purified phosphopeptides. Asterisks (*) mark the places where 
a putative tryptic cleavage site has failed to cleave in phosphorylated 
cdc25C. 
and ArgZz3, have not been cleaved or have been poorly  cleaved 
by trypsin,  and  these minor cuts may account for some of the 
additional minor phosphopeptides present on the two-dimen- 
sional maps. By comparison of the two-dimensional migration 
of each of the purified phosphopeptides sequenced with the 
pattern obtained with the  total tryptic phosphopeptides from 
in vivo and in vitro phosphorylated cdc25, we can identify 
that  at least five of the six sites (Thr4', T h P ,  Ser'22, Thr130, 
and Ser2l4, respectively designated as 1, 2, 3-4, and 6 on the 
maps shown in Fig. 3) were also phosphorylated in cdc25 from 
a mitotic population of human fibroblasts (Fig. 3B).  Site 5, 
T h P ,  also seems to be phosphorylated in cdc25 from mitotic 
cells, although the overall level is lower in comparison with 
the effective phosphorylation observed in vitro at  this site. 
All six phosphorylation sites identified on human cdc25C are 
outside the conserved region present in all cdc25 genes (con- 
taining the catalytic site)  and  are located in the NHP-terminal 
part of the molecule. Examining cdc25 proteins from other 
sources, we have observed a comparable NHz-terminal  distri- 
bution pattern  and number of potential p34cdc2-~y~lin B kinase 
phosphorylation sites (human cdc25-A 11 x SP, 2 x TP; 
human cdc25-B: 12 X SP, 2 X TP; hamster cdc25C: 5 X SP, 
4 x TP; Xenopus cdc25: 7 x SP, 6 x TP; Drosophilalstring: 
5 X SP, 3 X TP; S. pombe: 6 X SP, 3 X TP and S. cerevisiae: 
7 X SP) suggesting that a similar ~34"~'-dependent phos- 
phorylation may take place in cdc25 from other species (dis- 
cussed below). In summary, comparison of the in vitro and in 
vivo phosphopeptides from phosphorylated cdc25C  shows that 
cdc25C is phosphorylated in mitotic human fibroblasts on at 
least five sites that are also specifically phosphorylated by 
~34 '~" '  protein kinase in  vitro. 
Effect of the Phosphorylation by p34cdc2-Cyclin B Protein 
Kinase on the Activity of cdc25C In  Vitro and in GP Mammalian 
Fibroblasts-To examine the effects of phosphorylation of 
cdc25  by  cdc2 on the activity of cdc25C, we developed a system 
that involved an in vitro phosphorylation reaction coupled to 
immunoprecipitation and desalting to remove other reaction 
components. cdc25 proteins were reacted with purified p3pdC2- 
cyclin B kinase complex and either ATP or ADP or with ATP 
alone, without the kinase complex. Fig. 5 shows an electro- 
phoretic analysis of the resulting reaction components. cdc25 
proteins were initially phosphorylated in  vitro, and  then  the 
cdc2 kinase components were completely removed by immu- 
noprecipitation with anti-cyclin B antibodies bound to protein 
A-Sepharose beads (as previously described in Strausfeld et 
al., 1991). Proteins remaining in the supernatant fraction 
were silver stained  after  SDS-PAGE  and  are shown in Fig. 
5A. Besides cdc25 protein (shown by immunoblotting also in 
Fig. 5A) ,  no other  protein components remain in the super- 
natant except for one band at 40 kDa, clearly visible on the 
blot in lanes 2 and 3 but also present in lane I albeit with a 
higher shifted Mr. This band is a  natural cleavage product of 
cdc25; as mentioned for Fig. 1, it was also visible in the 
phosphorylation reaction, indicating that  it would represent 
an NHz-terminal breakdown product. To confirm that no 
residual ~34'~'' protein kinase was present  in the  supernatant 
fractions following immunoprecipitation with anti-cyclin B, 
the  supernatants were immunoblotted with anti-PSTAIR  an- 
tibodies and show that no residual kinase was detected in any 
of the reactions (Fig. 5B) (even when exposing the blot for 
ECL detection up to 15  min). As control, the staining for the 
cdc2 kinase used in  the phosphorylation reactions is shown 
(Fig. 5B, lane K ) .  Greater than a 3000-fold dilution of this 
kinase was necessary to lose the ECL signal (data  not shown). 
Similarly, no H1 kinase activity was detected in the super- 
natant fractions, either without or  after  a 20-min preincuba- 
tion (Fig. 5C).  These data demonstrate that  p34'~2-cyclin B 
kinase was completely depleted from the cdc25 protein  frac- 
tions. 
As reported before for phosphorylated cdc25 at mitosis in 
Xenopus oocytes and HeLa cells (Kumagai and Dunphy, 1992; 
Izumi et  al., 1992; Hoffmann et al., 1993), on one-dimensional 
Laemmli PAGE, cdc25 protein phosphorylated by cdc2-cyclin 
B kinase migrates with a lower mobility in comparison with 
the nonphosphorylated form (Fig. 5A, compared lane 1 with 
lunes 2 and 3 ) .  This complete shift in mobility, visible both 
by silver staining and by immunoblotting with anti-cdc25, 
shows that the cdc25 protein in reaction 1 has all been 
quantitatively phosphorylated by  cdc2 kinase when the reac- 
tion was performed in the presence of ATP. 
Using the highly purified phosphorylated or nonphosphor- 
ylated cdc25C proteins (obtained from reactions 1-3), we 
investigated if changes in in vitro activity accompanied phos- 
phorylation. Although various pseudosubstrates have been 
used previously in  other in vitro studies, we chose to concen- 
trate  on  the dephosphorylation and activation of the physio- 
logical substrate of cdc25,  cdc2 prokinase alone. cdc25C pro- 
teins were incubated with prokinase for 4  and 20 min in  the 
absence of ATP (to prevent eventual prokinase-dependent 
phosphorylation of cdc25C). Thereafter, aliquots of the reac- 
tion mixture were diluted in the reaction mixture used to 
assay histone 1 kinase activity in a reaction similar to  that 
described for Fig. 1. Under these reaction conditions (Fig. 5 0 )  
there is little detectable difference in activity after 4 min of 
incubation for prokinase activation, but after 20 min of in- 
cubation of cdc25 with the prokinase, a 2-3-fold increase in 
histone 1 kinase activity is detected with the phosphorylated 
cdc25C sample. We repeatedly observed such a difference in 
activity, and  the  data shown in Fig. 5 0  represent the mean of 
eight in vitro prokinase activation measurements. AS a  con- 
trol, the incubation of the prokinase alone shows that it 
contains  little  or no H1 kinase activity on its own (compare 
with the level of buffer alone in Fig. 50) .  Increasing the 
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FIG. 5. PAGE, immunoblot, and activity  analysis of human cdc25C phosphorylated in vitro with p34*'* protein kinase. 
Human cdc25C protein was incubated  together with p34'd"-cyclin B kinase (reactions 1 and 2) or  alone  (reaction 3) in the presence of ATP 
(reactions 1 and 3 )  or  ADP  (reaction 2) as described under  "Experimental Procedures." p34'd'z-cyclin B kinase was removed by immunopre- 
cipitation with  anti-cyclin B antibodies  bound to protein A-Sepharose beads. Phosphorylated  or  nonphosphorylated cdc25 protein  (reaction 
2 or 2 + 3, respectively) remaining  in  the  supernatant was  analyzed on SDS-polyacrylamide gel and  either silver stained  (first three lanes 
marked stain) or  immunoblotted with anti-cdc25  antibodies (lanes marked blot). The sizes of the molecular weight markers (M) are indicated 
in  kDa  together  with  the position of unphosphorylated cdc25C (lower  arrow) and  phosphorylated cdc25 (upper  arrow). In panel R is shown 
an immunoblot of the  supernatants from reactions 1-3 as  shown  in panel A ,  reacted with anti-PSTAIR antibodies, to  detect  any residual 
~ 3 4 ~ ~ ~ '  protein kinase. As a control, lane K shows  the  immunoreactivity of the  same  amount of p34'd'2 kinase as used in reactions 1 and 2 
(exposure time for the ECL detection, 15 s). Panel C, relative histone H1 kinase activity in aliquots (1/50 of the total volume) of the 
supernatant  fractions of reactions 1-3 after  immunoprecipitation of  p34'dc2-cyclin B kinase. Controls were as follows: assay  with  1/50  of the 
total  amount of  p34'd'2-cyclin B kinase used to  phosphorylate cdc25 protein  in reaction I and 2 (kinase) or with buffer only (buffer). Panel D, 
phosphorylated  and  unphosphorylated cdc25C proteins (reactions 1-3 above) were incubated with  purified  inactive  cdc2-prokinase.  After  4 
and 20 min of incubation a t  4 "C, samples were removed and assayed for histone 1 kinase activity. Shown is a histogram of the relative 
incorporation of counts/min  into  histone HI for the  different reaction mixtures. The  data shown represent  the mean of eight individual 
experiments,  and  standard  deviations for each value are  also  represented.  Controls showing H1 kinase  activity of the  prokinase  alone  and 
buffer  (from the  prokinase  activation  incubation  step)  are shown. 
incubation  time for prokinase  activation by cdc25 up  to 60 1992). We next examined if in  vitro phosphorylation by pu- 
min did not  result  in significantly  higher H1 kinase  activity rified p34cd'2-cyclin B kinase brought  about changes in cdc25 
(data not shown). This 2-3-fold increase in the activity of activity  in living human  and  rat  fibroblasts  through microin- 
phospho-cdc25 toward  prokinase  is very similar  to  that de- jection of the phosphorylated and unphosphorylated cdc25 
scribed previously comparing  the  activity of cdc25 immuno- proteins  into synchronized cells. Since  one dogmatic problem 
precipitated from interphase and mitotic Xenopus extract in assaying the in vitro phosphatase activity of cdc25 has 
using a similar  assay  (Izumi et al., 1992; Kumagai and  Dunphy, involved the extent of renaturation of the bacterially ex- 
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pressed cdc25 proteins,  initial  studies  examined if cdc25 pro- 
teins could undergo the  correct cytolocale after injection into 
growing cells. For  these  studies cells growing on glass  cover- 
slips were microinjected  with the purified  cdc25 proteins  and 
a t  different  times  thereafter fixed and  stained for the local- 
ization of cdc25. We (Girard et al., 1992) and  others  (Millar 
et al., 1991a)  have previously shown that  in  rat  and  human 
fibroblasts cells, cdc25 proteins  are  predominantly localized 
in the nucleus. Fig. 6 shows the cytolocale of microinjected 
cdc25 proteins in REF-52 cells a t  10 (Fig. 6 A )  and 30 min 
FIG. 6. Microinjection  of  purified  cdc25  protein  into  mam- 
malian  fibroblasts. T o  assess the in vivo effect of elevating intra- 
cellular levels of  cdc25 protein, purified  cdc25 protein from  bacteria 
was  microinjected into rat embryo fibroblasts at  a concentration of 
0.2 mg/ml. At different times thereafter, cells were fixed and stained 
for the distribution of  cdc25 protein visualized with rabbit anti-cdc25 
polyclonal antibodies as described  (Girard et al., 1992). Panel A,  cells 
microinjected  with  purified  cdc25 protein and fixed 10 min afterward. 
Panel B, cells microinjected with purified  cdc25 protein and fixed 30 
min after. Panel C, cells microinjected  with  cdc25C protein that was 
inactive in the prokinase activation assay due to repeated freeze- 
thawing and fixed 60 min after microinjection. Injected cells are 
shown by arrows in each panel. Nuclear staining of the endogenous 
cdc25 protein is visible for uninjected cells in each panel. 
(Fig. 6 B )  after microinjection. In all cases cells were microin- 
jected in the cytoplasm. Whereas in the initial stages after 
injection the  protein  is localized both in the cytoplasm and in 
the nucleus, after 30 min, proteins have essentially fully 
relocated into the nucleus. (Note the staining for injected 
cdc25 protein is brighter  than  the endogenous cdc25 staining 
in  uninjected cells.) To confirm that  this would not occur with 
cdc25C proteins  that were inactive or  denatured, we microin- 
jected a sample of cdc25C proteins  that  had lost the capacity 
to induce prokinase  activity in uitro due to repeated freeze- 
thawing. In  this case the  protein  remains exclusively localized 
in the cytoplasm and does not show translocation into the 
nucleus after 60 min (Fig. 6C). These  data clearly show that 
our bacterially expressed and purified active cdc25 protein 
contains  the  conformational  information necessary for trans- 
location to  the nucleus. Hence  on  the basis of these observa- 
tions  it would appear unlikely that  the cdc25 proteins we have 
injected are improperly refolded or  denatured. 
Since we have  shown  before that microinjection of active 
purified  p34cdc22-cyclin B kinase produces morphological 
changes that mimic prophase entry into mammalian cells 
(Lamb et al., 1990), the  induction of such changes provides a 
good means of detecting  the  potential  activation of endoge- 
nous ~ 3 4 ' ~ ' ~  kinase activity in uiuo. Clearly, however, with the 
microinjection of a marked excess of nonphosphorylated 
cdc25C protein,  apart from the  translocation  to  the nucleus, 
little  or  no evidence of morphological or  structural changes  in 
injected cells was observed (Fig. 6, A and B ) .  This would 
suggest that,  unlike  the in uitro system,  in which addition of 
nonphosphorylated cdc25 is sufficient to induce p34'd'2-cyclin 
B kinase activation, in mammalian cells the  activation of the 
prokinase does not occur  with nonphosphorylated cdc25 pro- 
tein alone. However, as shown in Figs. 7 and 8, when cells in 
Gz were injected with  the purified cdc25 protein  that  had been 
phosphorylated by p34'dc2-cyclin B kinase as described in Fig. 
5, marked  changes in cell morphology were observed. Within 
15 min of injection of the phosphorylated cdc25 protein, 
injected cells began to undergo retraction of the cytoplasm 
and  round  up  in a way similar  to  prophase  entry (Fig. 8A, 
cells designated by arrows), an effect that reached its peak 30 
min following injection  (see Fig. 7 ,  A and B and Fig. 8 B )  and 
started  to reverse by 60 min  after injection (Fig. 8C). Note 
that  the cells in Fig. 8, A-C were photographed when still 
living, whereas the cells in Fig. 7 were photographed after 
fixation, immunofluorescence  processing, and mounting, and 
this  last  treatment  results  in a poorer quality of the phase 
contrast images. In Fig. 8, D and E, to  demonstrate  that  the 
cells  showing  a rounding  up morphology are specifically the 
ones  that have  been  injected with cdc25, injected cells have 
been fixed after 30 min  and  stained for the presence of mouse 
IgGs, coinjected as a marker for injected cells. As shown in 
Fig. 8E, two cells were injected in  that field, which both show 
retraction of their cytoplasm and rounding up (cells desig- 
nated by arrows in Fig. 8 0 ) .  These effects were specific to  the 
phosphorylated cdc25 protein since both injection of prepa- 
ration 2  (cdc25 recovered after  incubation with p34cd'2-cyclin 
B kinase and  ADP)  or  preparation 3 (cdc25 incubated  alone 
with ATP) showed a  complete lack of effect (Fig. 7 ,  C and D )  
and  Table  I).  Furthermore, microinjection of the level of cdc2 
kinase used  for the in uitro phosphorylation  experiment 
(-0.015 mg/ml) was on its own insufficient to induce any 
prophase-like  changes in morphology (data  not shown). This 
is consistent with our previous  observations  describing that 
levels of kinase 5-10-fold higher are necessary to induce  such 
effects (Lamb et al., 1990). The prophase-like  phenotype 
induced by cdc2-phosphorylated cdc25 was exactly  similar to 
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FIG. 7. In vivo activity of phosphorylated or nonphosphorylated cdc25 protein. We investigated if phosphorylation of cdc25 
protein changed its in oioo activity through microinjection of purified phosphorylated cdc25C prepared as described in Fig. 5, reaction I (and 
reactions 2 and 3 as  a  control)  into rat embryo fibroblasts synchronized in G2. Cells were fixed 40 min after microinjection and stained for 
the distribution of cdc25 and mouse marker-injected IgGs. Shown are phase contrast (panels A and C )  or fluorescence micrographs of  cells 
stained for cdc25 protein (panels B and D). Panels A and B show cells injected with cdc25 protein that had been phosphorylated by ~34'~''- 
cyclin B kinase and immunodepleted from the kinase as shown in Fig. 5 (reaction I ), and paneels C and D show cells injected with 
nonDhosDhorvlated cdc25 Drotein incubated with ATP (Fia.  5, reaction 3 ) .  Shown by arrows in each panel are the injected cells  as identified 
with the-staining for mouse marker IgGs (not  shown). 
.I . 
the effects we reported before of injecting active cdc2 kinase 
into interphase mammalian cells (Lamb et al., 1990). Like 
cdc2 kinase injection, phosphorylated cdc25 did  not induce 
any  detectable  nuclear envelope  breakdown and induced only 
a  limited extent of chromatin  condensation  (data  not  shown). 
However, unlike  the effects of purified  active cdc2 kinase  that 
were elicited  in Go, GI, and Gz cells and  maintained for hours, 
reversing  only  when reaching  S-phase  (for Go and GI cells) or 
at  mitosis (for GB cells) (Lamb et al., 1990), the effects of 
phosphorylated cdc25 were only  observed  when injecting cells 
in GZ (i.e. no effect was observed when  phosphorylated cdc25 
was  injected  in Go, GI, or  S-phase cells; data  not  shown)  and 
were readily  reversing by 60 min  after injection (Fig. 8C) and 
completely  reversed within 90-120 min. These  results could 
be obtained  in a variety of cell lines  including human  embry- 
onic and  adult fibroblasts,  Swiss 3T3 cells, CV1 monkey cells, 
and  HeLa cells. In  addition,  the effects could be prevented if 
the  phosphorylated cdc25C (or cdc2 kinase) was denatured by 
boiling prior  to injection (data  not  shown).  The reversal of 
this cell-rounding  effect of microinjected  phospho-cdc25 can 
be  delayed through  treatment of injected cells with 100 nM 
okadaic  acid, a concentration  that presumably inhibits  phos- 
phatase type 2A activity (data not shown). The last data 
correlate with the previous observations made on Xenopus 
oocytes for the  dephosphorylation of mitotic cdc25 proteins 
that were found to be okadaic acid-sensitive (Kumagai  and 
Dunphy, 1992; Izumi et al., 1992). In  addition, preincubation 
of phosphorylated cdc25 proteins with the purified  catalytic 
subunit of phosphatase 2A was sufficient to prevent cell 
rounding, further  demonstrating  that only the phosphorylated 
form of cdc25C is  competent  to induce  changes  in morphology 
(data  not  shown).  Table I summarizes the overall extent of 
the effects  observed with  the injection of the  three different 
preparations of cdc25 proteins. Taken together, these data 
show that only after cdc25C protein is phosphorylated by 
p34'd'2-cyclin B kinase  is  it  competent  to induce changes  in 
cell morphology similar  to  those observed following injection 
of active p34'd'2-cyclin B kinase, suggesting that such  phos- 
phorylation of cdc25C phosphatase makes it highly efficient 
in  vivo to activate cells into a premature prophase-like  phe- 
notype through its catalytic action on endogenous p34'd'2- 
cyclin B prokinase. 
DISCUSSION 
We have shown that cdc25 phosphatase is an effective 
substrate in  vitro for p34'd'2-cyclin B protein kinase and shows 
a marked increase in  phosphorylation in living human fibro- 
blasts at  the  transition Gz-M. Comparative phosphopeptide 
mapping coupled with gas-phase sequencing allowed us to 
identify that  the  same  sites were phosphorylated in vivo a t  
mitosis as  phosphorylated in vitro by cdc2-cyclin B kinase. 
Finally,  microinjection into  interphase  rat embryo or  human 
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TABLE I 
Effects of phosphorylated and nonphosphorylated cdc25C protein 
microinjected into  early G2 REF-52 cells 
The values given represent the sum of four different microinjection 
experiments performed under "blind assay conditions" with solutions 
1, 2, and 3. 
Solution injected into GI Cells rounded up"/ I n ~ ~ ~ ~ ~ l l s  
cells total injected cells effect 
96 
1. Phospho-cdc25 + ATP 1501153 98 
2. cdc25 + ADP 01142 0 
3. cdc25 + ATP 0/89 0 
' Cells  lose their normal flattened morphology and substrate an- 
choring in a prophase-like phenotype as previously  observed  following 
injection of active cdc2 kinase. 
fibroblasts showed that only the phosphorylated form of hu- 
man cdc25C  was capable of activating the endogenous p34cdc2 
prokinase in vivo because it induces effects similar to those 
observed following microinjection of active p34'd'2-cyclin B 
kinase. 
Although genetic studies in yeast and Drosophila suggest 
that cdc25 acts in  a  dose-dependent  manner in the activation 
of mitosis (Russell and Nurse, 1986; Edgar and O'Farrell 
1989), in  most other cell types including Xenopus (Jessus  and 
Beach, 1992; Kumagai and Dunphy, 1991), HeLa  (Millar et 
al., 1991a), and two nontransformed  human or rat cell lines 
(Girard et al., 1992), cdc25 levels are  invariant hroughout the 
cell cycle. This observation implies that regulation and acti- 
vation of cdc25 at  mitosis must involve posttranslational 
modifications. Cyclic changes in Xenopus cdc25 electropho- 
retic mobility and in uitro tyrosine  phosphatase  activity could 
be correlated to  the increased phosphorylation of sites in the 
amino terminus (Kumagai and Dunphy 1992; Izumi et al., 
1992). Similar  studies  using  glutathione  S-transferase-human 
cdc25C fusion protein confirmed that mitotic extracts from 
HeLa cells could phosphorylate and increase the in uitro 
activity of cdc25C and reported that immunodepletion of 
these M-phase extracts with anti-p34'd'2 or anti-cyclin B 
antibodies prevented such phosphorylation of cdc25 (Hoff- 
man et al., 1993). A key issue to understanding the regulation 
of cdc25C  was therefore the identity of the kinase responsible 
for its phosphorylation at  mitosis. 
The present study shows that cdc25C protein in human 
fibroblasts becomes phosphorylated at  mitosis on the same 
sites  as phosphorylated in uitro by highly purified cdc2-cyclin 
B and identifies these sites precisely by sequencing. Since 
direct evidence that ~ 3 4 ' ~ ' ~  protein kinase is the kinase re- 
sponsible for the phosphorylation of cdc25 at  mitosis relies 
on  the comparison and identification of the sites phosphoryl- 
ated in uitro and in uiuo, precise analysis of these  sites was 
essential.  We have repeatedly observed five phosphopeptides 
when analyzing either in uiuo or in uitro phosphorylated cdc25. 
It is unclear why Hoffman et al. (1993) have detected only 
FIG. 8. The in vivo effects of phosphorylated cdc25 are 
rapidly reversed. In a delineated area, rat embryo fibroblast (REF- 
52) cells in GZ were microinjected with phosphorylated cdc25 as for 
Fig. 7, panels A and B,  and  the same field of cells was photographed 
by phase contrast at 15, 30, and 60 min after injection. Shown by 
arrows are three injected cells in the field. Like for Fig. 7, marker 
antibodies were included in the injection, and after 90 min, cells  were 
fixed and stained for the presence of these marker antibodies to 
confirm the identification of the injected cells, together with the use 
of time lapse video  microscopy. In panels D and E, cells have  been 
fixed after 30 min and stained for the presence of marker antibodies, 
to prove the cells injected. Two cells clearly rounded up and shown 
by arrows in panel D are shown to be injected in panel E. 
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two phosphopeptides for human cdc25 (which apparently 
resolved in opposing directions from the origin, when all 
tryptic peptides should migrate toward the cathode at  pH 
1.9). One possibility, at least concerning the in vivo phos- 
phorylation, is that because these authors peptide mapped 
cdc25C from nocodazole-blocked cells (therefore already in 
metaphase), their system may have been insensitive in de- 
tecting some of the activation phosphorylation sites. In ad- 
dition,  as  illustrated  under "Results" (Fig. 2), it is very un- 
likely that by using only one-dimensional separation of an 
immunoprecipitate one can guarantee to separate human 
cdc25C from other more abundant and variably insoluble 
phosphoproteins such as members of the intermediate fila- 
ment family. Indeed, even by two-dimensional analysis, such 
separation remained critical. Comparison of the sites found 
phosphorylated in vivo in cdc25C to  the consensus sequence 
derived from other mapped sites on different protein sub- 
strates for the cdc2-cyclin B protein kinase (reviewed in 
Moreno and Nurse (1990)) shows the presence of polar/basic 
residues before and/or  after the  S/T-P site  in five of the six 
sites we have identified. The exception, site 5 (serine 167), 
although undergoing substantial phosphorylation in vitro, 
shows little if any phosphorylation i n  vivo. This observation 
is in agreement with the conclusion that  the sites we have 
identified i n  vivo correspond to true cdc2-cyclin B protein 
kinase substrates. 
With  the evidence that ~ 3 4 " ~ '  protein kinase phosphoryl- 
ates  the same sites as  the ones responsible for the phosphoryl- 
ation/activation of cdc25C at mitosis, it was important to 
examine whether such phosphorylation would bring detecta- 
ble changes in the biological activity of cdc25, i.e. against  its 
specific substrate, ~ 3 4 ' ~ '  protein kinase inside living mam- 
malian cells.  We  show that, when injected into Gz nontrans- 
formed rat embryo fibroblasts, phosphorylated cdc25 proteins 
were extremely efficient a t  activating changes in cell shape 
and morphology, an effect not observed with even 10-fold 
higher concentrations of the nonphosphorylated form of 
cdc25. Thus although nonphosphorylated cdc25 does show 
phosphatase activity i n  vitro, it does not produce an effect in 
cells. The 2-fold increase of in vitro activity of cdc25C by 
phosphorylation underlies a profound change in its i n  vivo 
function. 
The effects of phospho-cdc25C were  very similar to those 
observed after injection of purified p34&'-cyclin B kinase in 
that they were mostly affecting the cell shape  and cytoskele- 
ton to mimic a prophase phenotype, without any nuclear 
envelope breakdown and only a limited extent of chromatin 
condensation (Lamb et al., 1990). However, we could clearly 
discount that these effects resulted from contaminating 
p34'k2-cyclin B kinase in a number of ways. 1) The superna- 
tant containing phosphorylated cdc25 after immunoprecipi- 
tation of p34"&'-cyclin B was checked to be devoid of any 
residual kinase by two criteria, absence of H1 kinase activity 
and absence of any detectable PSTAIR-reacting  antigen. 2) 
Unlike the changes induced by injection of purified active 
p34'k2-cyclin B kinase, the effects of phosphorylated cdc25 
protein were only induced in Gz cells and reversed within 60- 
90 min after injection. That injected cdc25 protein  can only 
have an effect in Gz cells is consistent with the fact that 
p34ck2-cyclin B kinase activation does not only involve Tyr''/ 
Thr" dephosphorylation but also requires its phosphorylation 
on threonine 161, an event that occurs only after cdc2 protein 
kinase becomes associated with cyclin subunits, i.e. from S- 
phase onward (Krek  and Nigg, 1991). 
cdc25, being a  serine/threonine-rich molecule, is likely to 
contain  a  putative  substrate  site for various protein kinases. 
I n  vitro, we have observed that CAMP-dependent protein 
kinase, mitogen-activated protein kinase, and calcium cal- 
modulin-dependent protein kinase 2 can phosphorylate cdc25 
albeit much less efficiently than cdc2 kinase. However, these 
phosphorylations appear to be without significant effect on 
the biological activity of cdc25, assessed by  microinjection.' 
Among the members of the cdc2-like kinase family, we have 
also observed that both cdc2-cyclin A and cdk2-cyclin A can 
phosphorylate cdc25 i n  vitro, an observation3 contrasting with 
that reported by Hoffman et al. (1993). However, several lines 
of evidence support that the cyclin B-complexed form of 
p34cdc2 protein kinase is the most likely to be involved in 
the phosphorylation of cdc25C at mitosis. First, of the known 
regulatory proteins that activate cdc2 kinases, only cyclin B 
shows the punctual marked increase in abundance during the 
late G2-M phase  transition. Thus if kinases of the Cdk family 
were involved in  the activation of cdc25, they would have to 
complex with cyclin  B. Second, cdc25, as  an activator of MPF, 
has high affinity for the p34"&'-cyclin B kinase and tran- 
siently forms an in vivo protein complex with the ~34'~''- 
cyclin B kinase (Gautier et al., 1991; Jessus and Beach, 1992). 
However, there  are clearly additional modulatory mechanisms 
acting on cdc25C during GZ since at  that time cells have both 
Thr161-phosphorylated ~ 3 4 ' ~ '  prokine kinase and low levels 
of cyclin  B. One possibility is that cdc25,  which  was found to 
be essentially nuclear (Millar et al., 1991a; Girard et al., 1992), 
and cdc2 proteins  are spatially separated from  cyclin B, which 
is thought to be cytoplasmically localized (Pines  and  Hunter, 
1991). In  this case some event  acting on either cdc25 or cyclin 
B  must  take place to allow their  interaction. In  that respect, 
we note that injected phosphorylated cdc25C is not  as highly 
concentrated  in the nucleus as  the nonphosphorylated cdc25 
(Fig. 7B uersus D). Additionally, as discussed by Kumagai 
and  Dunphy (1992)) a second enzymatic activity that regulates 
the activation of cdc25 is the protein  phosphatase responsible 
for dephosphorylating cdc25. Since phosphorylation of cdc25 
by ~ 3 4 " ~ '  protein kinase induces such marked changes in 
cells, the phosphatase that modulates this process must be of 
paramount importance. In Xenopus, both phosphate type 1 
and 2A can effectively dephosphorylate cdc25 and  inhibit  its 
in vitro activity (Kumagai and Dunphy, 1992; Izumi et al., 
1992). In mammalian cells we have observed that low levels 
of the phosphatase inhibitor okadaic acid are sufficient to 
prolong the effects of phosphorylated cdc25C suggesting that 
in vivo the phosphatase activity acting on cdc25C is more 
likely to be the type 2A form. Although okadaic acid treatment 
alone is inconclusive (the levels of inhibitor that penetrate 
the cells cannot be determined), such a role for type 2A 
phosphatase would  be in agreement with the observation that 
INH, an inhibitory activity that prevents mitotic activation 
in Xenopus, is a type 2A-related phosphatase (Lee et al., 
1991). However, since phosphatase 2A is a multimeric protein, 
further  studies  are  still required to determine which form of 
the enzyme would  be responsible for the inhibition of cdc25 
activation. 
The results obtained from the injection of the cdc25C 
protein  phosphatase also underline an interesting finding with 
respect to  the cytolocale of cdc25C and of cdc2 activation at 
mitosis. We observed that denatured forms of the protein 
remain in the cytoplasm after injection, whereas active cdc25 
proteins  are quickly translocated  into the nucleus. This ob- 
servation confirms that cdc25C is predominantly a nuclear 
protein in mammalian cells and suggests that the events 
involved in the activation of cdc2 protein kinase are  either 
A. Fernandez and N. J. C. Lamb, unpublished observations. 
A. Fernandez and N. J. C. Lamb, unpublished observations. 
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restricted within the nucleus or  take place only after cdc25 
has  translocated to  the cytoplasm. The process we have de- 
scribed here suggests that  the phosphorylation of cdc25 by 
p34c*2-cyclin B kinase may  be part of a positive autocatalytic 
activation loop (see model Fig. 7 in Izumi et al., 1992)), in 
which cdc25 activates p34ch2-cyclin B kinase that,  in  turn, 
phosphorylates cdc25 and  activates  further p34cdc2-cyclin B 
kinase. The interesting possibility is that different cdc25 
proteins  are responsible for differentially dephosphorylating 
the various members of the Cdk protein kinase family. For 
human cdc25 proteins, there is clearly a precedent since 
cdc25A and cdc25B appear to activate cdc25 phosphatase 
activity in the absence of cdc2 protein kinase but in the 
presence of cyclin B (Galaktionov and Beach, 1991). They 
would thus induce the initial  activation of cdc2-cyclin B with 
the subsequent phosphorylation of cdc25C inducing the hy- 
peractivation of cdc2 protein kinase. In such  a process the 
role of the cdc25C phosphorylation would  be to stimulate  a 
sufficiently high level of cdc2 protein kinase activity to si- 
multaneously overcome the counteracting  protein phospha- 
tases and drive cells into mitosis. However, the need for 
phosphorylation of cdc25 is questionable since untreated 
cdc25  shows in  vitro phosphatase activity (Gautier et al., 1991; 
Dunphy and Kumagai, 1991;  Lee et al., 1992). Moreover, in 
Xenopus the interphase form of cdc25X has  intrinsic in  vitro 
phosphatase activity (Kumagai and Dunphy, 1992). In our in 
vivo assay only the cdc25 protein phosphorylated by cdc2 
showed an effect, whereas even up to a 10-fold excess of 
unphosphorylated cdc25C  was without  any detectable mitotic 
effect. (We have estimated from immunoblotting defined 
quantities of cell extracts  against purified cdc25C proteins, 
the concentration of which was estimated from amino acid 
analysis, that  the intracellular  concentration of cdc25C pro- 
tein is of the order of 10 pg/ml.) Such an all-or-nothing 
response in vivo contrasts with the  data obtained in vitro by 
others (Izumi et al., 1992; Kumagai and Dunphy, 1992) and 
in this study comparing the activity of phosphorylated and 
unphosphorylated cdc25C measured against cdc2 prokinase. 
Phospho-cdc25C exhibited only a 2-4-fold higher activity 
than  the unphosphorylated forms, whereas when using a crude 
Xenopus cell extract  instead of purified cdc2 prokinase, more 
than a 20-fold increase in H1 kinase activation was found 
with the phosphorylated form of cdc25C (Hoffmann et al., 
1993). These discrepancies between the  data obtained in vitro 
with highly purified components and either in vitro data 
obtained with crude extracts or our in vivo microinjection 
data strongly suggest that some additional factors related to 
the  state of phosphorylation of cdc25C are involved in the 
regulation of its activation in  vivo. Unphosphorylated cdc25C 
may interact with proteins that would exert an inhibitory 
effect on it,  or alternatively phospho-cdc25 may complex or 
draw into  a complex with cdc2 factors integral to  the ampli- 
fication effect. Such mechanisms would  allow a  further level 
of control on MPF activation and will require further inves- 
tigation. Nonetheless, the mapping of the phosphorylation 
sites on cdc25 and  the microinjection experiments described 
here clearly show that phosphorylation of cdc25C by cdc2- 
cyclin B kinase is a key step in the induction of mitotic 
activation in living mammalian cells. 
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